3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Genitourinary
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Laryngeal Diseases
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
5
Nivolumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
regorafenib
1
niraparib
1
larotrectinib
1
futibatinib
1
durvalumab
1
dostarlimab
1
dabrafenib
1
cemiplimab
1
TAS-116
1
Ramucirumab
1
Itraconazole
1
Gemcitabine
1
Fluorouracil
1
Docetaxel
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Antibodies
1
4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
niraparib
×
Head & Neck
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled